National Center for Tumor Diseases (NCT) Heidelberg
Lars Riedemann, MD is a Consulting Neurologist at University Hospital Heidelberg and a Physician-Scientist at National Center for Tumor Diseases (NCT) Heidelberg, DKFZ German Cancer Research Center, and Habilitas GbR. Lars is also a Co-Founder and Scientific Director at Shift Medical, and a Guest Lecturer at Mannheim Business School. In the past, Lars has worked at prestigious institutions such as Harvard Medical School, Massachusetts Institute of Technology, and University Hospital Muenster. Their work focuses on advancing medical technology and improving healthcare through research and innovation.
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.